PHARMACYTE BIOTECH, INC.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $12.2K | $66.6K | $126.0K |
| Cost of Revenue | — | — | $0 | $0 | $0 | $9.6K | $19.4K | $32.1K |
| Gross Profit | — | — | $0 | $0 | $0 | $2.5K | $47.2K | $93.9K |
| Gross Margin | — | — | — | — | — | 20.9% | 70.9% | 74.5% |
| Operating Expenses | ||||||||
| Research & Development | $2.0M | $1.2M | $1.4M | $3.5M | $323.5K | $0 | — | — |
| SG&A Expense | $1.8M | $744.8K | $2.3M | $2.2M | $1.9M | $617.3K | $416.2K | $237.0K |
| Operating Income | $-7.0M | $-4.4M | $-6.1M | $-13.3M | $-19.0M | $-1.7M | $-1.9M | — |
| Operating Margin | — | — | — | — | — | -13,851.7% | -2,928.5% | — |
| Interest Expense | $0 | $1.5K | $1.2K | $4.9K | $20.0K | $154.4K | $230.1K | $171.7K |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | — | — |
| Net Income | $-6.8M | $-4.4M | $-6.1M | $-9.9M | $-27.3M | $-1.6M | $-1.9M | $-1.4M |
| Net Margin | — | — | — | — | — | -13,142.3% | -2,853.6% | -1,109.3% |
| EPS (Basic) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Shares Outstanding (Basic) | 10.66B | 9.30B | 8.28B | 7.75B | 6.42B | 4.85B | 4.12B | 3.85B |
| Shares Outstanding (Diluted) | 10.66B | 9.30B | 8.28B | 7.75B | 6.42B | 4.85B | 4.12B | 3.85B |
| Dividends Per Share | — | — | — | — | — | — | — | — |